Tradestie Institutional Equity Comparison Engine

FDMT vs CGEM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEM Overall Edge

CGEM Captures Institutional Edge (4โ€“0 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cullinan Therapeutics, Inc. Common Stock (CGEM) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, FDMT trades at N/M Forward P/E with -222.7% operating margin (+4505.6% YoY revenue) versus CGEM at 6.7x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against CGEM sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEM
FDMT N/M vs CGEM 6.7x Fwd P/E
Growth & Margin Winner CGEM
Op Margin -222.7% vs 0.0% ยท YoY +4505.6% vs +0.0%
Momentum & Technical Winner CGEM
1Y +13.3% vs +17.5% ยท 52W Pos 47% vs 12%
Options & Structure Winner CGEM
BREAKDOWN (10th %ile IV) vs UNCLASSIFIED (9th %ile IV)
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
CGEM NASDAQ
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.72
-5.45% 1D
Market Cap $653.8M
1M Return -24.83%
1Y Return +17.53%
Forward P/E 6.7x
Unified AI Score
48.4 / 100 HOLD
Tech 45.0 Fund 51.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FDMT +13.33% CGEM +17.53% Spread: +4.2 pp (CGEM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
FDMT TTM Op. Margin: -222.7% CGEM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FDMT vs CGEM. Trailing 12-month operating profitability (FDMT -222.7% vs CGEM 0.0%) and valuation multiples (FDMT N/M vs CGEM 6.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FDMT (4) vs CGEM (6)
Institutional Metric FDMT CGEM Criterion Row Winner
Market Capitalization Scale $669.3M $653.8M Larger Scale FDMT
Trailing P/E Ratio Valuation N/M 6.7x Lower Multiple CGEM
Forward P/E Ratio Valuation N/M 6.7x Lower Multiple CGEM
Revenue Growth (YoY) Growth +4505.6% +0.0% Higher Growth FDMT
Operating Margin (TTM) Profitability -222.7% 0.0% Higher Margin CGEM
Net Profit Margin Profitability -208.6% 0.0% Higher Margin CGEM
Return on Equity (ROE) Capital Efficiency -56.7% -50.3% Higher ROE CGEM
52-Week Range Position Momentum 47% ($7โ€“$17) 12% ($8โ€“$23) Stronger Trend FDMT
Beta / 30D Volatility Risk Regime 1.89ฮฒ ยท 90% Vol 1.56ฮฒ ยท 104% Vol Lower Realized Risk FDMT
Unified Institutional Score Composite Signal 42.1 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite CGEM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FDMT vs CGEM Buy Guide
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGEM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live CGEM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FDMT nor CGEM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.